Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, neuroscience, and covid-19 diseases. The company's products include Revlimid, an oral immunomodulatory drug for the treatment of multiple myeloma; Eliquis, an oral inhibitor for reduction in risk of stroke/systemic embolism in NVAF, and for the treatment of DVT/PE; Opdivo for anti-cancer indications; Pomalyst/Imnovid indicated for patients with multiple myeloma; and Orencia for adult patients with active RA and psoriatic arthritis. It also provides Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia; Yervoy for the treatment of patients with unresectable or metastatic melanoma; Abraxane, a protein-bound chemotherapy product; Reblozyl for the treatment of anemia in adult patients with beta thalassemia; and Empliciti for the treatment of multiple myeloma. In addition, the company offers Zeposia to treat relapsing forms of multiple sclerosis; Breyanzi, a CD19-directed genetically modified autologous T cell immunotherapy for the treatment of adult patients with relapsed or refractory large B-cell lymphoma; Inrebic, an oral kinase inhibitor indicated for the treatment of adult patients with myelofibrosis; and Onureg for the treatment of adult patients with AML. It sells products to wholesalers, distributors, pharmacies, retailers, hospitals, clinics, and government agencies. The company was formerly known as Bristol-Myers Company. The company was founded in 1887 and is headquartered in New York, New York.
Employees - 34100,
CEO - Dr. Christopher S. Boerner Ph.D.,
Sector - Healthcare,
Country - US,
Market Cap - 96.56B
Altman ZScore(max is 10): 1.8, Piotroski Score(max is 10): 9, Working Capital: $6713000000, Total Assets: $92427000000, Retained Earnings: $16106000000, EBIT: 4659000000, Total Liabilities: $74979000000, Revenue: $47636000000
- Current Price $47.46 - Analyst Target Price $56.79| Ticker | BMY |
| Index | S&P 500 |
| Curent Price | 47.46 |
| Change | -2.54% |
| Market Cap | 96.56B |
| Average Volume | 13.24M |
| Income | -8948.00M |
| Sales | 48.30B |
| Book Value/Share | 8.05 |
| Cash/Share | 5.34 |
| Dividend Est | 2.48 (5.23%) |
| Dividend TTM | 2.44 (5.14%) |
| Dividend Ex-Date | Apr 04, 2025 |
| Employees | 34100 |
| Moving Avg 20days | -10.45% |
| Moving Avg 50days | -16.05% |
| Moving Avg 200days | -11.89% |
| Shares Outstanding | 2.03B |
| Earnings Date | Apr 24 BMO |
| Inst. Ownership | 79.83% |
| Price/Earnings | - |
| Forwad P/E | 7.86 |
| PE Growth | - |
| Price/Sales | 2.00 |
| Price/Book | 5.89 |
| Price/Cash | 8.89 |
| Price/FCF | 6.93 |
| Quick Ratio | 1.15 |
| Current Ratio | 1.25 |
| Debt/Equity | 3.13 |
| Return on Assets | -9.53% |
| Return on Equity | -39.10% |
| Return on Investment | -13.70% |
| Gross Margin | 56.80% |
| Ops Margin | 18.51% |
| Profit Margin | -18.53% |
| RSI | 25.62 |
| BETA(β) | 0.42 |
| From 52week Low | 20.60% |
| From 52week High | -25.07% |
| EPS | -4.43 |
| EPS next Year | 6.03 |
| EPS next Qtr | 1.68 |
| EPS this Year | 493.92% |
| EPS next 5 Year | 72.58% |
| EPS past 5 Year | - |
| Sales past 5 Year | 15.21% |
| EPS Y/Y | -214.24% |
| Sales Y/Y | 7.32% |
| EPS Q/Q | -95.92% |
| Sales Q/Q | 7.54% |
| Sales Surprise | 4.73% |
| EPS Surprise | 20.43% |
| ATR(14) | 1.94 |
| Perf Week | -3.61% |
| Perf Month | -19.85% |
| Perf Quarter | -20.47% |
| Perf Year | -3.13% |
| Perf YTD | -16.10% |
| Target Price | 56.79 |
AryaFin Engine© - An AI FinTech Venture - 2024-25 Disclaimer